[Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results].
Alexey BoykoK Z BakhtiyarovaO V BoykoV A DudinL G ZaslavskyN A MalkovaYe V ParshinaI Ye PoverennovaStella SivertsevaN A TotolyanS G ShchurF A KhabirovZoya A GoncharovaMaria ZakharovaD D BolsunArina V Zinkina-OrikhanYulia N LinkovaT V ChernovskayaA A PorozovaPublished in: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (2023)
Treatment with samPEG-IFN-β1a is an effective and safe first-line therapy for relapsing-remitting multiple sclerosis patients.
Keyphrases
- multiple sclerosis
- clinical trial
- white matter
- double blind
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- immune response
- placebo controlled
- disease activity
- randomized controlled trial
- prognostic factors
- study protocol
- combination therapy
- systemic lupus erythematosus
- patient reported outcomes
- smoking cessation